Brief: 2Seventy Bio And JW Therapeutics Announce Intent To Expand Strategic Partnership To Accelerate The Research And Development Of T Cell-Based Immunotherapies & Autoimmune Therapies

2Seventy Bio

12/09/2023 12:05

Sept 12 (Reuters) - JW (Cayman) Therapeutics Co Ltd
 2126.HK :
    * 2SEVENTY BIO AND JW THERAPEUTICS ANNOUNCE INTENT TO EXPAND
STRATEGIC PARTNERSHIP TO ACCELERATE THE RESEARCH AND DEVELOPMENT
OF T CELL-BASED IMMUNOTHERAPIES AND AUTOIMMUNE THERAPIES
    * 2SEVENTY BIO INC - INITIAL MAGE-A4 T-CELL COLLABORATION
PROGRAM
SET TO ENTER CLINIC AHEAD OF SCHEDULE BY END OF 2023
    * 2SEVENTY BIO INC - COMPANIES PLAN TO ADD PROGRAMS IN
ONCOLOGY
AND AUTOIMMUNE DISEASE TO COLLABORATION

Source text for Eikon:  ID:nBwbRSZVa 
Further company coverage:  2126.HK 

 ((Reuters.Brief@thomsonreuters.com;))